← Alignment Healthcare, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $207.3m | $466.6m | $409.5m | $202.9m | $432.9m | $575.8m | |
| Accounts receivable (less allowance for credit losses of $833 at December 31, 2025 and $0 at December 31, 2024) | $40.1m | $58.5m | $92.9m | $119.7m | $153.9m | $253.2m | |
| Prepaid expenses and other current assets | $17.2m | $27.7m | $42.1m | $45.0m | $37.1m | $94.1m | |
| Total current assets | $264.7m | $552.9m | $544.5m | $483.5m | $661.6m | $951.6m | |
| Property and equipment, net | $27.1m | $30.4m | $37.2m | $51.9m | $67.1m | $64.3m | |
| Goodwill | — | — | $34.8m | $34.8m | $34.8m | $32.1m | |
| Intangible assets, net | — | — | $5.5m | $5.3m | $4.5m | $4.5m | |
| Right of use asset, net | $9.9m | $7.9m | $5.8m | $10.0m | $7.8m | $7.0m | |
| Other assets | $2.1m | $4.7m | $6.0m | $6.4m | $6.1m | $6.3m | |
| Investments - current | $207.3m | — | $0 | $115.9m | $37.8m | $28.4m | |
| Medical expenses payable | $112.6m | $125.9m | $170.1m | $205.4m | $289.8m | $474.6m | |
| Long-term portion of lease liabilities | $10.3m | $7.0m | $3.7m | $9.0m | $7.8m | $6.5m | |
| Total Alignment Healthcare, Inc. stockholders' equity | $30.6m | $306.0m | $238.1m | $156.9m | $99.9m | $179.3m | |
| Total assets | $338.5m | $630.9m | $633.9m | $591.9m | $782.1m | $1.1b | |
| Total liabilities and stockholders' equity | $338.5m | $630.9m | $633.9m | $591.9m | $782.1m | $1.1b | |
| Accounts payable and accrued expenses | $15.7m | $17.4m | $32.3m | $23.5m | $22.1m | $33.3m | |
| Accrued compensation | $25.2m | $23.9m | $27.5m | $34.1m | $39.9m | $49.0m | |
| Total current liabilities | $153.5m | $167.2m | $230.0m | $263.0m | $351.8m | $556.9m | |
| Long-term debt, net of debt issuance costs | $144.2m | $150.6m | $160.9m | $161.8m | $321.4m | $323.2m | |
| Total liabilities | $307.9m | $324.8m | $394.6m | $433.8m | $681.1m | $886.5m | |
| Preferred stock, $.001 par value; 100,000,000 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $.001 par value; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 204,153,619 and 191,778,639 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 164k | 188k | 187k | 189k | 192k | 205k | |
| Additional paid-in capital | $410.0m | $880.7m | $970.2m | $1.0b | $1.1b | $1.2b | |
| Accumulated deficit | ($379.6m) | ($574.9m) | ($732.2m) | ($880.3m) | ($1.0b) | ($1.0b) | |
| Noncontrolling interest | $0 | $15k | $1.2m | $1.1m | $1.1m | $0 | |
| Total stockholders' equity | $30.6m | $306.1m | $239.3m | $158.1m | $101.0m | $179.3m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.